ARTICLE | Company News
Seattle Genetics, Mabtech cancer MAb deal
March 14, 2002 8:00 AM UTC
Mabtech (Nacka, Sweden) granted SGEN an exclusive license to certain monoclonal antibodies that target cell surface molecules on a variety of cancer cells. SGEN said it will evaluate the antibodies as...